Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana Alarcon

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 11, 2024
Metabolic Tumor Volume Response after Bridging Therapy Determines Chimeric Antigen Receptor T-Cell Outcomes in Large B-Cell LymphomaHarper Hubbeling, Doris Leithner, Emily A Silverman, et al.
Blood Advances|August 25, 2021
Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cellsMartina Pennisi, Miriam Sanchez-Escamilla, Jessica R Flynn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2021
Impact of <i>TP53</i> Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell TherapyRoni Shouval, Ana Alarcon Tomas, Joshua A Fein, et al.
Journal of Hematology & Oncology|April 22, 2024
Conventional and novel [<sup>18</sup>F]FDG PET/CT features as predictors of CAR-T cell therapy outcome in large B-cell lymphomaDoris Leithner, Jessica R Flynn, Sean M Devlin, et al.
Leukemia|November 6, 2022
Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphomaAna Alarcon Tomas, Joshua A Fein, Shalev Fried, et al.
Blood Advances|September 10, 2021
The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCTRoni Shouval, Joshua A Fein, Christina Cho, et al.
Eclinicalmedicine|June 19, 2026
Fertility management and outcomes after CAR T-cell therapy: an international survey from the Cellular Therapy and Immunobiology working party of the European Society for Blood and Marrow TransplantationGiorgio Orofino, Isabel Sánchez-Ortega, Juana Schwartz Mota, et al.
Haematologica|July 14, 2022
Allogeneic transplant following CAR T-cell therapy for large B-cell lymphomaJoanna Zurko, Jeremy Ramdial, Mazyar Shadman, et al.
Nature Medicine|April 1, 2025
An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphomaSandeep S Raj, Teng Fei, Shalev Fried, et al.
The New England Journal of Medicine|February 27, 2020
Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell TransplantationJonathan U Peled, Antonio L C Gomes, Sean M Devlin, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 11, 2024
Metabolic Tumor Volume Response after Bridging Therapy Determines Chimeric Antigen Receptor T-Cell Outcomes in Large B-Cell LymphomaHarper Hubbeling, Doris Leithner, Emily A Silverman, et al.
Blood Advances|August 25, 2021
Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cellsMartina Pennisi, Miriam Sanchez-Escamilla, Jessica R Flynn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2021
Impact of <i>TP53</i> Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell TherapyRoni Shouval, Ana Alarcon Tomas, Joshua A Fein, et al.
Journal of Hematology & Oncology|April 22, 2024
Conventional and novel [<sup>18</sup>F]FDG PET/CT features as predictors of CAR-T cell therapy outcome in large B-cell lymphomaDoris Leithner, Jessica R Flynn, Sean M Devlin, et al.
Leukemia|November 6, 2022
Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphomaAna Alarcon Tomas, Joshua A Fein, Shalev Fried, et al.
Blood Advances|September 10, 2021
The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCTRoni Shouval, Joshua A Fein, Christina Cho, et al.
Eclinicalmedicine|June 19, 2026
Fertility management and outcomes after CAR T-cell therapy: an international survey from the Cellular Therapy and Immunobiology working party of the European Society for Blood and Marrow TransplantationGiorgio Orofino, Isabel Sánchez-Ortega, Juana Schwartz Mota, et al.
Haematologica|July 14, 2022
Allogeneic transplant following CAR T-cell therapy for large B-cell lymphomaJoanna Zurko, Jeremy Ramdial, Mazyar Shadman, et al.
Nature Medicine|April 1, 2025
An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphomaSandeep S Raj, Teng Fei, Shalev Fried, et al.
The New England Journal of Medicine|February 27, 2020
Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell TransplantationJonathan U Peled, Antonio L C Gomes, Sean M Devlin, et al.
Pageof 6